stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) Gross margin
HUTCHMED (China) Limited Sponsored ADR's gross margin over the twelve months to 30 June 2023 was 44.4%. Over the past ten years it has ranged from 17.3% (fiscal 2020) to 54.1% (fiscal 2023); the current reading is higher than 82% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 53.5% and below the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 38.7% | (5.96) |
| FY2024 | 44.6% | (9.48) |
| FY2023 | 54.1% | 27.08 |
| FY2022 | 27.0% | (0.45) |
| FY2021 | 27.5% | 10.18 |
| FY2020 | 17.3% | (4.53) |
| FY2019 | 21.8% | (10.93) |
| FY2018 | 32.8% | 5.66 |
| FY2017 | 27.1% | (0.54) |
| FY2016 | 27.7% | (10.19) |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2023 | 60.9% | 38.37 |
| Dec 2022 | 22.5% | (9.54) |
| Jun 2022 | 32.1% | 8.99 |
| Jun 2021 | 23.1% | 2.71 |
| 10 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | 97.9% |
| XERS Xeris Biopharma Holdings, Inc. compare | 87.4% |
| ANIP ANI Pharmaceuticals, Inc. compare | 61.1% |
| TRLV Trulieve Cannabis Corp. compare | 60.6% |
| PBH Prestige Consumer Healthcare Inc. compare | 52.5% |
| HCM HUTCHMED (China) Limited Sponsored ADR | 44.4% |
| ALVO Alvotech compare | 42.7% |
| PRGO Perrigo Company plc compare | 32.3% |
| RGC Regencell Bioscience Holdings Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 53.5% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement